Neos Therapeutics, Inc
NEOS
NEOS was delisted on the 19th of March, 2021.
69 hedge funds and large institutions have $65M invested in Neos Therapeutics, Inc in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 24 increasing their positions, 22 reducing their positions, and 9 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 22
5% less funds holding
Funds holding: 73 → 69 (-4)
26% less capital invested
Capital invested by funds: $88.1M → $65M (-$23.1M)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
88% less call options, than puts
Call options by funds: $66K | Put options by funds: $533K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.72M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.29M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$1.1M |
| 4 |
JP Morgan Chase
New York
|
+$939K |
| 5 |
EIM
Essex Investment Management
Boston,
Massachusetts
|
+$293K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSC
Lyon Street Capital
Sausalito,
California
|
-$3.83M |
| 2 |
FPC
Falcon Point Capital
San Francisco,
California
|
-$1.53M |
| 3 |
DM
Deerfield Management
New York
|
-$1.46M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$1.3M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$666K |
NEOS Hedge Fund Activity: Q3 2018 in Review
69 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Neos Therapeutics, Inc (NEOS) for Q3 2018, worth a combined $65M — down 26% from $88.1M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of NEOS and 5 opened new positions — a net loss of 4 holders — while 22 trimmed existing stakes and 24 added.
The largest buyer was Sphera Funds Management, adding an estimated $2.72M. The largest seller was Lyon Street Capital, cutting an estimated $3.83M.
- 69 institutional investors held Neos Therapeutics, Inc (NEOS) as of Q3 2018, down from 73 in Q2 2018.
- Funds reported $65M of Neos Therapeutics, Inc stock for Q3 2018, down 26% quarter-over-quarter.
- 5 funds opened new Neos Therapeutics, Inc positions in Q3 2018 and 9 closed out, a net change of -4 holders.
- The largest Neos Therapeutics, Inc buyer in Q3 2018 was Sphera Funds Management, an estimated $2.72M added.
- The largest Neos Therapeutics, Inc seller in Q3 2018 was Lyon Street Capital, an estimated $3.83M sold.
Based on aggregated 13F filings for Q3 2018.